Table 3.

Univariate and multivariate analyses for overall survival in the whole study population.

Variables	Univariate analyses		Multivariate analyses
	p value	HR (95% CI)	p value	HR (95% CI)
Men	0.42	1.14 (0.83–1.55)
Age	0.26	1.01 (0.99–1.03)	0.67	1 (0.98–1.02)
Diabetes	0.56	0.55 (0.07–4.07)
Alcohol addiction	0.75	0.72 (0.1–5.42)
Performance status
2 versus 0–1	0.07	1.56 (0.96–2.56)
0 versus 1–2	0.06	1.47 (0.98–2.22)	0.7	0.92 (0.59–1.42)
Tumour location
Head (ref)	1	1
Body	0.42	0.85 (0.57–1.27)
Tail	0.79	1.05 (0.74–1.5)
Number of metastatic sites	0.045	1.25 (1.01–1.55)	0.51	1.1 (0.83–1.47)
Peritoneal carcinomatosis	0.08	1.36 (0.97–1.9)	0.031	1.7 (1.05–2.74)
Liver metastases	0.009	1.64 (1.13–2.39)	0.004	2.28 (1.31–3.97)
Pulmonary metastases	0.25	0.79 (0.53–1.18)
Lymph node metastases	0.62	0.91 (0.61–1.34)
Bone metastases	0.66	1.18 (0.55–2.53)
CA19.9 at baseline	0.026	1 (1–1)	0.045	1 (1–1)
Albumin	0.08	0.97 (0.95–1)
Bilirubin	0.13	1 (1–1.01)
Folfirinox versus gemcitabine/nab-paclitaxel	0.008	0.65 (0.48–0.90)	0.021	0.62 (0.41– 0.93)

CI, confidence interval; HR, hazard ratio.